Alector (ALEC) Free Cash Flow (2018 - 2026)
Alector's (ALEC) quarterly Free Cash Flow came in at -$34.2 million in Q2 2026, up 30.19% year-over-year from -$26.3 million in Q2 2025, and up 31.41% quarter-over-quarter from -$49.9 million in Q1 2026.
Analysis
Alector (ALEC) Free Cash Flow (2018 - 2026) Analysis & Trends
Alector (ALEC) has reported Free Cash Flow for 9 consecutive years, with -$34.2 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Free Cash Flow rose 30.19% year-over-year to -$34.2 million in Q2 2026; TTM through Jun 2026 was -$158.4 million, a 26.67% increase from a year earlier, with the FY2025 full-year figure at -$184.1 million, up 20.37% from the prior year.
- Free Cash Flow was -$34.2 million for Q2 2026 at Alector, up from -$49.9 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $134.4 million in Q1 2022 and troughed at -$63.1 million in Q2 2024.
- A 5-year average of -$39.5 million and a median of -$49.6 million in 2022 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow soared 350.56% in 2022 and sank 136.88% in 2023, its largest moves.
- Over 5 years, Free Cash Flow stood at -$49.7 million in 2022, then increased by 6.82% to -$46.3 million in 2023, then fell by 19.22% to -$55.2 million in 2024, then climbed by 24.47% to -$41.7 million in 2025, then grew by 17.85% to -$34.2 million in 2026.
- The last three Free Cash Flow figures came in at -$34.2 million (Q2 2026), -$49.9 million (Q1 2026), and -$41.7 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 3.49 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 3.43 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.01 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 572.80 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -563.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 408.00 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Alector | 274.68 Mn | 101.88 Mn | - | -34.25 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -34.25 Mn |
| Mar 31, 2026 | -49.93 Mn |
| Dec 31, 2025 | -41.69 Mn |
| Sep 30, 2025 | -32.52 Mn |
| Jun 30, 2025 | -49.06 Mn |
| Mar 31, 2025 | -60.80 Mn |
| Dec 31, 2024 | -55.20 Mn |
| Sep 30, 2024 | -50.95 Mn |
| Jun 30, 2024 | -63.13 Mn |
| Mar 31, 2024 | -61.88 Mn |
| Dec 31, 2023 | -46.30 Mn |
| Sep 30, 2023 | -46.45 Mn |
| Jun 30, 2023 | -44.22 Mn |
| Mar 31, 2023 | -49.57 Mn |
| Dec 31, 2022 | -49.69 Mn |
| Sep 30, 2022 | -50.97 Mn |
| Jun 30, 2022 | -58.19 Mn |
| Mar 31, 2022 | 134.40 Mn |
| Dec 31, 2021 | -49.82 Mn |
| Sep 30, 2021 | 444.14 Mn |